Dynamic metrics-based biomarkers to predict responders to anti-PD-1 immunotherapy

BACKGROUND: Anti-PD-1 immunotherapies have shown clinical benefit in multiple cancers, but response was only observed in a subset of patients. Predicting which patients will respond is an urgent clinical need, but current companion diagnosis based on PD-L1 IHC staining shows limited predictability....

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Can, He, Hua, Li, Xiaobing, Su, Maureen A., Cao, Yanguang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6353899/
https://www.ncbi.nlm.nih.gov/pubmed/30587849
http://dx.doi.org/10.1038/s41416-018-0363-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6353899/
https://www.ncbi.nlm.nih.gov/pubmed/30587849
http://dx.doi.org/10.1038/s41416-018-0363-8

Ejemplares similares